ClinicalTrials.gg
RecruitingNCT07592962WILLUpdated May 18, 2026

Whole-life Investigation of Lishui Longevity

An observational study in Ischemic Stroke, Chronic Disease and Cardiovascular, sponsored by The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital. Recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,500
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
24th of 188
4,500 · median 625
Started
2026
with 124 others
Observational
188 of 754
108 open now
Primary completion
2036-05
later than 398 of 399 live
Registered
687th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 24th largest by planned enrollment of the 188 observational ones that give a count, is one of 125 that started in 2026, is one of 188 observational ones, reaches primary completion later than 398 of the 399 other live ones, and was the 687th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

  1. To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors.
  2. To carry out targeted intervention and long-term follow-up for high-risk populations, reduce the incidence risk of major chronic diseases in the target population, improve residents' health status and grassroots comprehensive prevention and treatment capacity of chronic diseases, and provide scientific evidence and practical support for the construction of Healthy Lishui.
Read the detailed description

This project will establish a cohort related to stroke and tumors, with 4500 subjects selected from the 30-80-year-old urban-rural integrated population in Lishui City, covering both urban and rural residents in the urban-rural junction area of the region. This population, with diverse living habits and uneven access to medical resources, is a key group for the prevention and control of stroke and tumors, and its selection can reflect the epidemiological characteristics of the two diseases in Lishui.

To achieve the research goal, the subjects will be randomly divided into three groups for targeted detection, with specific schemes as follows:

Group A: Magnetic Resonance (MR) examination (focusing on the head and neck to identify cerebrovascular and tissue abnormalities) and methylation pan-cancer detection (non-invasive and high-sensitivity, used to screen for early methylation abnormal changes of tumor-related genes).

Group B: Methylation pan-cancer detection (consistent with Group A), Transcranial Doppler (TCD) examination (for intracranial hemodynamic monitoring), cervical ultrasound (for assessing cervical artery conditions), and Vibration-Controlled Transient Elastography (VCTE) examination (for detecting liver elasticity).

Group C: Physiological age methylation detection (evaluating the real physiological aging state through the methylation level of age-related CpG sites) and VCTE examination (consistent with Group B) to supplement liver function-related detection.

The core purpose of this project is to explore the three-dimensional distribution (time, place, and population distribution) of stroke and tumors in this population. Time distribution aims to explore the variation rules of incidence rates across different seasons, years, and age stages; regional distribution aims to analyze the differences in incidence rates among different urban-rural junctions and their correlation with environmental and medical resource factors; population distribution aims to identify high-risk groups by analyzing the differences in incidence rates among different genders, ages, living habits, and physiological aging states.

In addition, this project will clarify the correlation between each detection indicator and the two diseases, improve the construction of biological sample banks and databases, provide a scientific basis for establishing a community-hospital linked intervention system, thereby improving the early detection rate and intervention rate of diseases and protecting the health of residents

03

Conditions studied

  • Ischemic Stroke
  • Chronic Disease
  • Cardiovascular

Keywords

  • acute ischemic stroke
  • carotid artery stenosis
  • Hepatic fibrosis
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of 4,500 participants aged 30-80 years recruited from 10 urban and 10 rural sites in Lishui City using a cluster sampling method. Participants are randomly divided into three equal groups of 1,500 each, receiving different examination protocols. The collected data are further analyzed and grouped into cerebrovascular, tumor, and epigenetic age categories based on the respective test results.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 30 to 80 years old; male-to-female ratio of 1:1; permanent residents in Lishui City; physically healthy; voluntary participation in the project with signed .

Exclusion criteria

Exclusion Criteria:

  • Individuals ever diagnosed with malignant tumors or cardiovascular and cerebrovascular diseases by physicians or other health professionals; those with unstable vital signs or an expected survival time of less than 3 months; participants with incomplete basic information, and those unable to cooperate with subsequent follow-up.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,500 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cerebrovascular group

    Participants in the cerebrovascular group receive head and neck magnetic resonance (MR) examination, transcranial Doppler (TCD) and cervical ultrasound. These examinations are used to screen cerebrovascular structural lesions, intracranial hemodynamic disorders and cervical atherosclerotic plaques, so as to identify early risk factors for stroke and cerebrovascular diseases.

  • Tumor Group

    The tumor group undergoes methylation pan-cancer detection. This non-invasive and high-sensitivity assay is applied to screen aberrant methylation of tumor-related genes, covering ten common cancers including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer and pancreatic cancer, enabling early identification of potential malignant tumor risk in the population.

  • Epigenetic Age Group

    The epigenetic age group accepts physiological age methylation detection combined with Vibration-Controlled Transient Elastography (VCTE). Methylation profiling of age-related CpG sites is used to evaluate individual physiological aging status, while VCTE is supplemented to assess liver elasticity and related metabolic characteristics.

06

What researchers measure

Primary outcomes

  1. Prevalence rate of stroke and tumors

    A blood-based methylation pan-cancer assay was performed to screen for ten common malignancies, including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer, and pancreatic cancer. The prevalence of each cancer type was calculated as the number of confirmed positive cases divided by the total number of participants screened.

    Time frame: From enrollment to the end of the 10-year follow-up period

Secondary outcomes

  1. Unilateral carotid artery stenosis rate

    The degree of cervical vascular stenosis was detected and evaluated. The distribution of unilateral carotid artery stenosis rate (defined as stenosis degree \>50%) was analyzed, which was calculated as the number of participants with carotid stenosis greater than 50% divided by the total screened population.

    Time frame: From enrollment to the end of the 10-year follow-up period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pacinella G, Bona MM, Todaro F, Ciaccio AM, Daidone M, Tuttolomondo A. Tracing Inflammation in Ischemic Stroke: Biomarkers and Clinical Insight. Int J Mol Sci. 2025 Oct 8;26(19):9801. doi: 10.3390/ijms26199801. PubMed 41097065 ↗
  • Wang J, Li Y, Qi L, Mamtilahun M, Liu C, Liu Z, Shi R, Wu S, Yang GY. Advanced rehabilitation in ischaemic stroke research. Stroke Vasc Neurol. 2024 Aug 27;9(4):328-343. doi: 10.1136/svn-2022-002285. PubMed 37788912 ↗
  • Tao T, Liu M, Chen M, Luo Y, Wang C, Xu T, Jiang Y, Guo Y, Zhang JH. Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective. Pharmacol Ther. 2020 Dec;216:107695. doi: 10.1016/j.pharmthera.2020.107695. Epub 2020 Sep 28. PubMed 32998014 ↗
  • Zhao D, Guallar E, Qiao Y, Knopman DS, Palatino M, Gottesman RF, Mosley TH Jr, Wasserman BA. Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities). Circulation. 2024 Sep 10;150(11):838-847. doi: 10.1161/CIRCULATIONAHA.123.067003. Epub 2024 Aug 1. PubMed 39087353 ↗
  • Gilbertson RJ. Mapping cancer origins. Cell. 2011 Apr 1;145(1):25-9. doi: 10.1016/j.cell.2011.03.019. PubMed 21458665 ↗
  • Paleari L. Personalized Assessment for Cancer Prevention, Detection, and Treatment. Int J Mol Sci. 2024 Jul 26;25(15):8140. doi: 10.3390/ijms25158140. PubMed 39125710 ↗
  • Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27. doi: 10.1158/1055-9965.EPI-15-0578. Epub 2015 Dec 14. PubMed 26667886 ↗
  • Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, Wang L, Jiang Y, Li Y, Wang Y, Chen Z, Wu S, Zhang Y, Wang D, Wang Y, Feigin VL; NESS-China Investigators. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation. 2017 Feb 21;135(8):759-771. doi: 10.1161/CIRCULATIONAHA.116.025250. Epub 2017 Jan 4. PubMed 28052979 ↗
  • Hachinski V, Einhaupl K, Ganten D, Alladi S, Brayne C, Stephan BCM, Sweeney MD, Zlokovic B, Iturria-Medina Y, Iadecola C, Nishimura N, Schaffer CB, Whitehead SN, Black SE, Ostergaard L, Wardlaw J, Greenberg S, Friberg L, Norrving B, Rowe B, Joanette Y, Hacke W, Kuller L, Dichgans M, Endres M, Khachaturian ZS. Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement. 2019 Jul;15(7):961-984. doi: 10.1016/j.jalz.2019.06.001. PubMed 31327392 ↗
  • Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, Wadley VG. Trajectory of Cognitive Decline After Incident Stroke. JAMA. 2015 Jul 7;314(1):41-51. doi: 10.1001/jama.2015.6968. PubMed 26151265 ↗
  • Lourida I, Hannon E, Littlejohns TJ, Langa KM, Hypponen E, Kuzma E, Llewellyn DJ. Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA. 2019 Aug 6;322(5):430-437. doi: 10.1001/jama.2019.9879. PubMed 31302669 ↗
  • GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-480. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14. PubMed 30879893 ↗
  • GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8. PubMed 30496103 ↗
  • Zhao Y, Zhang X, Chen X, Wei Y. Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review). Int J Mol Med. 2022 Feb;49(2):15. doi: 10.3892/ijmm.2021.5070. Epub 2021 Dec 8. PubMed 34878154 ↗
  • Pan Y, Jing J, Cai X, Wang Y, Wang S, Meng X, Zeng C, Shi J, Ji J, Lin J, Lyu L, Zhang Z, Mei L, Li S, Li S, Zhu W, Li H, Wei T, Wang Y. PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)-a population-based prospective cohort study: rationale, design and baseline participant characteristics. Stroke Vasc Neurol. 2021 Mar;6(1):145-151. doi: 10.1136/svn-2020-000411. Epub 2020 Aug 30. PubMed 32863279 ↗

Individual participant data

Plan to share: No — The individual participant data (IPD) for this study will not be shared publicly due to concerns regarding participant privacy, data security, and the lack of an established data sharing agreement and platform. All data are stored and managed in accordance with applicable data protection regulations and institutional policies.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for May 2036, 120 months later.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 120 months is above that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 18, 2026
StartEst.
May 18, 2026
Primary completionEst.
May 31, 2036
CompletionEst.
May 31, 2036
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07592962
Lead sponsor
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital
Responsible party
Sponsor
First posted
May 18, 2026
Start date
May 18, 2026 (estimated)
Primary completion
May 31, 2036 (estimated)
Completion
May 31, 2036 (estimated)
Last update
May 18, 2026

Study contacts

Jingping Sun, PhD
Contact
lszxyysunjingping@yeah.net
86-18504713450
Jiansong Ji, PhD
study chair · The Central Hospital of Lishui City

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion